MedTrace Logo

Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

NCT04620187 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2026-04-13

No results posted yet for this study

Summary

This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland cancer. It will also examine the effectiveness of study drug Ado-trastuzumab (T) emtansine (DM1) on cancer recurrence.

Conditions

  • Salivary Gland Cancer
  • HER2 Gene Mutation

Interventions

DRUG

Ado-trastuzumab (T) emtansine (T-DM1)

Intravenous infusion ever 21 days (3weeks) for 1 year (52 weeks)

RADIATION

Standard of Care Radiotherapy

Radiotherapy to shrink or kill tumors

DRUG

Standard of Care Chemotherapy

Intravenous injection

Sponsors & Collaborators

Principal Investigators

  • Glenn J Hanna, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-24
Primary Completion
2028-02-01
Completion
2029-02-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04620187 on ClinicalTrials.gov